The technical core of the review concerns the kinase-phosphatase equilibrium that governs tau’s phosphorylation state. Tau is a natively unfolded protein that stabilizes microtubules in axons, and its function is tuned by the addition and removal of phosphate groups along its sequence, particularly in the proline-rich region and the microtubule-binding repeat region. When kinases such as glycogen synthase kinase-3 beta, cyclin-dependent kinase 5, microtubule affinity-regulating kinase 4, tau-tubulin kinase 1, tyrosine kinase 2 and cyclin-dependent kinase 3 outpace the phosphatases that oppose them, chiefly protein phosphatase 2A and protein phosphatase 1, hyperphosphorylated tau detaches from microtubules, misfolds and begins to self-assemble. The review emphasizes that this equilibrium is not a simple seesaw: individual kinases act at distinct sites and disease stages, which helps explain why broad kinase inhibition has proven difficult to translate into safe, effective therapies.

Equally important is the emerging picture of cross-talk among post-translational modifications. Phosphorylation does not act alone. The review details how O-GlcNAcylation, acetylation, ubiquitination, methylation, glycation and truncation by enzymes such as asparagine endopeptidase compete for overlapping residues and reshape tau’s conformational landscape. O-GlcNAcylation at serine and threonine residues, for instance, can sterically block phosphorylation at neighboring sites and appears protective in several models, suggesting that enhancing this sugar modification could be a viable strategy. Conversely, truncation of tau can expose aggregation-prone segments and accelerate the transition from soluble tau assemblies into paired helical filaments and straight filaments, the structural components of neurofibrillary tangles that cryo-electron microscopy has now resolved to near-atomic precision in patient brain tissue.

The review also highlights two systemic factors that have rarely been integrated into tau-centric models: nuclear envelope damage and iron metabolism. Hyperphosphorylated tau compromises the nuclear envelope and disrupts nuclear pore complexes, and interactions with the lamin B receptor contribute to DNA damage and transcriptional dysregulation in vulnerable neurons. Meanwhile, disturbed iron homeostasis pushes tau pathology toward ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation and reactive oxygen species. Advanced glycation end products further stabilize pathological tau species, creating a feed-forward loop in which oxidative stress, metal imbalance and protein misfolding reinforce one another. These mechanisms position tau as a node where metabolic stress and proteostatic failure converge, rather than a standalone culprit.

Perhaps the most conceptually ambitious section of the review extends tau pathology beyond neuronal boundaries. Pathological tau does not stay confined to the neurons that produce it. The authors describe how soluble tau species spread through tunneling nanotubes, extracellular vesicles and heparan sulfate proteoglycan-mediated uptake, seeding aggregation in recipient cells and propagating along anatomically connected networks, a pattern that resting-state functional MRI studies have begun to visualize in living patients. The low-density lipoprotein receptor-related protein 1 emerges as a key mediator of tau uptake and clearance, offering a potential point of therapeutic intervention. This network-level spread helps explain why tau burden follows predictable, stage-specific routes through the entorhinal cortex, hippocampus and association cortices rather than appearing randomly.

The review then situates tau within the broader ecosystem of Alzheimer’s disease, where it synergizes with amyloid-beta deposition to ignite neuroinflammation. Activated microglia and astrocytes release inflammatory mediators that both promote tau phosphorylation and impair its clearance. The blood-brain barrier, whose breakdown is increasingly recognized as an early event in the disease, permits peripheral immune molecules and plasma proteins to infiltrate the brain, further amplifying the inflammatory cascade. Strikingly, the authors extend this systems view to the gut-brain axis, citing evidence that gut dysbiosis and lipopolysaccharide-driven inflammation can modulate tau pathology through circulating immune signals. In this framework, tau phosphorylation behaves like a barometer of whole-body physiological state rather than an isolated intracellular defect.

On the translational front, the review surveys a new generation of biofluid biomarkers that are transforming how tau pathology is detected and tracked. Cerebrospinal fluid measures of phosphorylated tau have long served as diagnostic anchors, but plasma assays based on single-molecule array technology now achieve comparable diagnostic performance, opening the door to population-scale screening. Brain-derived tau, identified through immunoprecipitation-mass spectrometry, offers improved specificity for brain-derived over peripheral tau, while assays targeting the microtubule-binding repeat region may distinguish Alzheimer’s disease from other tauopathies, including chronic traumatic encephalopathy. The authors also point to emerging technologies such as organic electrochemical transistors that could enable point-of-care tau testing, potentially pairing fluid biomarkers with PET-based standardized uptake value ratios and resting-state functional MRI to stage disease with unprecedented resolution.

Therapeutically, the review maps a pipeline that extends well beyond the first generation of anti-tau antibodies. Monoclonal antibodies targeting specific phospho-epitopes are progressing through clinical trials, while antisense oligonucleotides aim to reduce tau production at the source. Small-molecule kinase inhibitors continue to be refined with attention to isoform selectivity. The most conceptually novel entry is a class of molecules the authors describe as dephosphorylation-targeting chimeras, or DEPTACs, which recruit phosphatases to phosphorylated tau in a manner analogous to the phosphorylation-targeting chimeras that recruit kinases. Related strategies include tauopathy-homing nanoassemblies designed to deliver payloads selectively to tau-bearing tissue. The review is careful to note that many of these modalities remain in early clinical investigation, and that target engagement, dosing windows and patient selection remain unresolved challenges.

The strategic implication of the review is that Alzheimer’s disease drug development may need to abandon the search for a single decisive target in favor of precision approaches aimed at the tau interactome. Because tau phosphorylation sits at the intersection of kinase signaling, proteostasis, nuclear integrity, metal metabolism, neuroinflammation and barrier function, interventions will likely need to be matched to the dominant pathogenic mechanisms operating in each patient, guided by fluid and imaging biomarkers that can stage both molecular pathology and network dysfunction. The authors frame their integrated model as a roadmap for such stratified trials, in which biomarker-defined subgroups receive mechanism-matched therapies.

For a field scarred by repeated late-stage failures, the reframing offered by this review is both sobering and energizing. It acknowledges that amyloid-centric therapies, including the recently approved antibody treatments, address only one strand of a tangled web, and that tau, with its stronger correlation to cognitive deterioration and synaptic dysfunction, offers a more direct line to the symptoms that matter to patients. Whether the multi-scale network view of tau phosphorylation can be converted into therapies that genuinely alter the course of Alzheimer’s disease will depend on the clinical performance of the biomarker and therapeutic platforms now moving through the pipeline, but the conceptual groundwork for that effort has, with this synthesis, been laid out in unusually complete detail.

Subject of Research: Tau phosphorylation mechanisms, network spread and therapeutic targeting in Alzheimer's disease

Article Title: Tau phosphorylation in Alzheimer’s disease: emerging mechanisms, network interactions, and therapeutic implications

Article References: Li, X., Zhang, L., Zhao, L., Qin, L., Bai, Q., Zeng, C., Gao, Z., Ni, J., Zeng, G., Saidova, A., Qing, H., & Li, H. (2026). Tau phosphorylation in Alzheimer’s disease: emerging mechanisms, network interactions, and therapeutic implications. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08889-2

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08889-2

Keywords: Alzheimer's disease, tau phosphorylation, neurofibrillary tangles, kinase-phosphatase equilibrium, post-translational modifications, neuroinflammation, blood-brain barrier, gut-brain axis, biomarkers, DEPTACs, antisense oligonucleotides, precision medicine